Elanco Animal Health (NYSE:ELAN) Issues Q4 2026 Earnings Guidance

Key Points

• Elanco guided to fourth-quarter 2026 EPS of $0.16–$0.19, a range that includes the $0.18 analyst consensus, and revenue of $1.2 billion, matching expectations.
• The company raised its full-year 2026 adjusted EPS outlook to $1.17–$1.20, above the $1.13 consensus; it also lifted full-year revenue guidance.
• Third-quarter results topped estimates: EPS was $0.27 versus $0.20 expected, while revenue reached $1.265 billion and grew 11% year over year.

Elanco Animal Health (NYSE:ELAN - Get Free Report) issued an update on its fourth quarter 2026 earnings guidance on Friday. The company provided EPS guidance of 0.160-0.190 for the period, compared to the consensus EPS estimate of 0.180. The company issued revenue guidance of $1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Elanco Animal Health also updated its FY 2026 guidance to 1.170-1.200 EPS.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock traded up $1.42 during trading on Friday, hitting $25.10. 2,556,983 shares of the company's stock traded hands, compared to its average volume of 5,580,083. Elanco Animal Health has a 1 year low of $19.40 and a 1 year high of $27.98. The business has a 50-day simple moving average of $23.11 and a 200-day simple moving average of $23.82. The stock has a market capitalization of $12.54 billion, a P/E ratio of -60.63, a PEG ratio of 2.25 and a beta of 1.73. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Friday, November 6th. The company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.07. The business had revenue of $1.26 billion during the quarter, compared to analyst estimates of $1.21 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. Elanco Animal Health's revenue was up 11.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.19 EPS. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. As a group, analysts forecast that Elanco Animal Health will post 1.13 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Morgan Stanley lowered their price objective on shares of Elanco Animal Health from $26.00 to $25.00 and set an "equal weight" rating on the stock in a research report on Thursday, October 29th. Jefferies Financial Group cut shares of Elanco Animal Health from a "buy" rating to a "hold" rating and dropped their target price for the stock from $31.00 to $24.00 in a report on Tuesday, October 20th. The Goldman Sachs Group assumed coverage on shares of Elanco Animal Health in a research report on Friday, October 16th. They issued a "buy" rating and a $32.00 target price for the company. UBS Group boosted their target price on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Finally, Weiss Ratings raised Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday, September 4th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Elanco Animal Health presently has an average rating of "Moderate Buy" and an average price target of $29.33.

Insider Buying and Selling at Elanco Animal Health

In other news, insider Timothy Bettington sold 4,350 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $23.00, for a total value of $100,050.00. Following the transaction, the insider owned 138,911 shares in the company, valued at $3,194,953. This represents a 3.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Michael Harrington acquired 5,000 shares of the company's stock in a transaction that occurred on Wednesday, August 12th. The stock was acquired at an average cost of $21.82 per share, for a total transaction of $109,100.00. Following the acquisition, the director owned 131,451 shares of the company's stock, valued at $2,868,260.82. The trade was a 3.95% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 48,998 shares of company stock worth $1,139,373 over the last 90 days. 1.14% of the stock is owned by company insiders.

More Elanco Animal Health News

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Third-quarter adjusted EPS of $0.27 topped the $0.20 consensus estimate, and revenue of $1.265 billion exceeded expectations of about $1.21 billion. Revenue rose 11% year over year, with 9% organic constant-currency growth. Elanco third-quarter results
• Positive Sentiment: Elanco raised 2026 adjusted EPS guidance to $1.17–$1.20, above the $1.13 consensus, and lifted revenue guidance to $5.155–$5.18 billion versus approximately $5.1 billion expected. It also increased its innovation revenue target and improved its year-end net leverage target to about 2.9x adjusted EBITDA. Elanco third-quarter results
• Positive Sentiment: Company survey results suggest resilient consumer demand: 93% of surveyed pet owners maintained or increased pet spending over the prior three months, supporting the outlook for pet-health products. Elanco consumer research
• Neutral Sentiment: Fourth-quarter revenue guidance of $1.2 billion matches consensus. EPS guidance of $0.16–$0.19 has a midpoint of $0.175, just below the $0.18 estimate, though the range includes consensus. Elanco third-quarter results

About Elanco Animal Health

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company's products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.